Presentations & Publications

2017 Investor Analyst Day

UPLOADED:

June 12, 2017

Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy

UPLOADED:

June 2, 2017

High-dose treatment with ADXS11-001, a Listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer

UPLOADED:

March 27, 2017

High-dose treatment with ADXS11-001, a Listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer

UPLOADED:

March 27, 2017

A prospective phase 2 trial (GOG-0265) of the Listeria-based HPV immunotherapy axalimogene filolisbac (AXAL) in second- and third- line metastatic cervical cancer: An NRG Oncology Group trial

UPLOADED:

March 13, 2017

HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity (#7632)

UPLOADED:

September 1, 2016

ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 [and stage 2] of the phase II GOG/NRG-0265 study

UPLOADED:

June 6, 2016

ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: Results from stage 1 [and stage 2] of the phase II GOG/NRG-0265 study

UPLOADED:

June 6, 2016

Immunotherapy of Breast Cancer: World Congress on Breast Cancer

UPLOADED:

December 1, 2015

Phase 1/2 study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): The KEYNOTE-046 trial

UPLOADED:

November 5, 2015

STAY TUNED

Mailing List

Sign up for email alerts for Press Releases and Advaxis' breaking news.

SOCIAL

Follow Us

Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.